Business
Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks
ST. LOUIS, December 15, 2025--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor’s nationwide expansion and broaden patient access to its immunotherapy-response diagnostics.
About this update from Labcorp Holdings Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/b0654cf849c25a9e9a80d426c4b71dee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/N6JzDdNnlVx1kIXRGYNKqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b0654cf849c25a9e9a80d426c4b71dee","width":480,"height":240}},"lazy":false},{"type":"text","content":"ST. LOUIS, December 15, 2025--(BUSINESS WIRE)--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor’s nationwide expansion and broaden patient access to its immunotherapy-response diagnostics.","length":389,"tagName":"p"},{"type":"text","content":"Ascension Ventures, the strategic investment arm of 13 leading U.S. health systems across 22 states, representing more than $100 billion in annual operating revenue, aligns closely with some of the nation’s largest oncology networks. Labcorp adds further strategic value through its national diagnostics footprint and rapidly expanding precision-oncology portfolio.","length":365,"tagName":"p"},{"type":"text","content":"Cofactor’s flagship assay, OncoPrism®, leverages machine-learning analysis of tumor RNA to quantify immune engagement and generate a clinically actionable predictive classification for immune checkpoint inhibitor (ICI) response. The platform’s capabilities were established in the national PREDAPT trial, which demonstrated multi-cancer applicability and performance exceeding that of existing clinically validated and Medicare-covered diagnostics. Importantly, OncoPrism moves beyond the constrained utility of prognostic biomarkers—delivering true predictive insight linked directly to ICI treatment outcomes. This positions OncoPrism as one of the few diagnostics capable of guiding immunotherapy use in both academic and community oncology settings, where advanced molecular tools have traditionally been difficult to adopt.","length":828,"tagName":"p"},{"type":"text","content":""This is a major step in ensuring that every patient—regardless of treatment location—has access to a predict...